Arena Pharmaceuticals, Inc. (ARNA)

[SpeculativeHoldings]

In bold is what I saw long before anyone published it in the Lancet...

Plain and simple, ARNA has the best candidate. You can go back through my previous posts to see why.

This also explains the sudden and rapid take off much higher than I had anticipated. I knew ARNA would go up after VVUS was snubbed, but I didn't imagine it would excel this quickly. Cheers to all.
____________________________________________________________________
Arena Pharma Shares Up; Editorial Raises Questions About Rival
26 minutes ago - Dow Jones News
NEW YORK -(Dow Jones)-

Arena Pharmaceuticals Inc.'s (ARNA) stock rose 14% on optimism for its experimental weight-loss drug Lorcaserin, after an editorial in a medical journal raised questions about the need for more data from a potential rival treatment.

The article, in The Lancet, covers a successful study by rival weight-loss drug developer Orexigen Therapeutics Inc. (OREX), but the editorial raises questions of whether more data are going to be needed to fully assess the drug's safety.

That is good news for Arena, because it has longer-term data, and the third company in the race to develop the latest crop of drugs, Vivus Inc. (VVUS), was recently snubbed by a U.S. Food and Drug Administration panel on concerns about not having enough data...